Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer is a research paper published in eLife (2025). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Neuroendocrine Tumor Research Foundation
Grant: 855538
Research Scholar Grant
Grant: RSG-22-167-01-MM
Research Scholar Grant
Grant: RSG-22-101-01-CDP
V Scholar
Grant: V2023-017
National Institutes of Health
Grant: R37-CA266270
National Institutes of Health
Grant: R03-AG073833
National Institutes of Health
Grant: R01-GM145884
National Institutes of Health
Grant: 3P30CA013696-21S1
CANCER CENTER CORE SUPPORT GRANT
National Institutes of Health
Grant: 3R37CA266270-03S1
Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
National Institutes of Health
Grant: 1R03AG073833-01A1
Deciphering Ang2/Tie2 signaling regulation of BBB disruption and neuroinflammation in Alzheimers disease
National Institutes of Health
Grant: 5R01GM145884-02
Deciphering the mechanism of non-canonical cell cycle entry
Fields of Study
Keywords